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ABSTRACT  
Although the role of complete gene inactivation by two loss-of-function mutations 
inherited in trans is well-established in recessive Mendelian diseases, we have not yet explored 
how such gene knockouts (KOs) could influence complex human phenotypes. Here, we 
developed a statistical framework to test the association between gene KOs and quantitative 
human traits. Our method is flexible, publicly available, and compatible with common genotype 
format files (e.g. PLINK and vcf). We characterized gene KOs in 4,498 participants from the 
NHLBI Exome Sequence Project (ESP) sequenced at high coverage (>100X), 1,976 French 
Canadians from the Montreal Heart Institute Biobank sequenced at low coverage (5.7X), and 
>100,000 participants from the GIANT Consortium genotyped on an exome array. We tested 
associations between gene KOs and three anthropometric traits: body mass index (BMI), height 
and BMI-adjusted waist-to-hip ratio (WHR). Despite our large sample size and multiple datasets 
available, we could not detect robust associations between specific gene KOs and quantitative 
anthropometric traits. Our results highlight several limitations and challenges for future gene KO 
studies in humans, in particular when there is no prior knowledge on the phenotypes that might 
be affected by the tested gene KOs. They also suggest that gene KOs identified with current DNA 
sequencing methodologies probably do not strongly influence normal variation in BMI, height, 
and WHR in the general human population. 
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INTRODUCTION 
 The identification of complete loss-of-function (LoF) alleles (i.e. genetic null or amorphic 
alleles) is a powerful strategy to characterize gene functions through random (e.g. chemical 
mutagenesis) or targeted (e.g. knockout (KO) methodology in the mouse, RNAi) genetic 
experiments. In contrast to model organisms, humans are not amenable to such genetic 
manipulations. Yet, there is tremendous biomedical interest in understanding how the complete 
disruption of both copies of a gene may impact human biology (1). Our complex physiology, 
interactions with our environment, and gene redundancy within our genome are only few of the 
reasons highlighting the importance of describing the phenotypic consequences of gene 
inactivation in humans. From a drug development perspective, the identification of humans with 
gene KOs also offers naturally occurring genetic experiments to assess the potential pleiotropic 
effects of candidate target genes (2).  
 
 Mendelian diseases, such as sickle cell anemia [MIM 603903] and cystic fibrosis [MIM 
219700], offer an entry point into the study of gene functions in humans. Indeed, the study of 
these conditions continues to yield important insights into human biology in health and disease 
(3). But only a limited number of genes have been implicated in Mendelian diseases: as of 
October 13 2015, there were 4,651 genes in the Online Mendelian Inheritance in Man (OMIM) 
database with phenotype-causing mutations. Furthermore, these mutations are often rare such that 
it is difficult to assemble sufficiently large cohorts of patients to study their pleiotropic effects. 
Gene KOs can have strong phenotypic effects on anthropometric traits in the context of 
Mendelian disorders or syndromes, as evident by mutations causing early-onset morbid obesity 
(PCSK1, LEPR) or dwarfism (GH1 GHR, ATR) (4-6). These mutations are rare (often private) 
and unlikely to be involved in anthropometric trait variation in the general population. However, 
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the possibility that gene KOs of more subtle effect might influence normal variation in 
anthropometric traits remains to be investigated.  
 
Large-scale whole-exome and -genome sequencing projects are beginning to 
systematically catalogue coding genetic variation in the human genome, including predicted LoF 
variants (7-11). On average, there are ~100-200 LoF variants per individual, resulting in ~20 
genes that are inactivated through homozygosity or compound heterozygosity (12). These 
numbers include mostly common variants, which are more likely to be phenotypically neutral 
given the effect of purifying selection (13). Limiting to variants with a minor allele frequency 
(MAF) <0.5%, the 1000 Genomes Project estimated that there are 10-20 LoF variants per 
individual (8). LoF variants are usually defined as variants that truncate protein sequences 
(nonsense and frameshift insertion-deletion (indel)) or that abrogate splice sites or stop codons 
(stop-loss) (12). Using this definition of LoF variant, and limiting their analyses to variants with a 
MAF <2%, Sulem et al. found that ~8% of 104,220 Icelanders carry at least one complete gene 
KO, and that most gene KOs are seen in <5 individuals (14).  
 
Recently, several studies have explored the link between gene KOs and human complex 
phenotypes, such as chronic diseases (12, 15-17) and autism (18). As mentioned above, it is well-
established that rare gene inactivation can cause extreme anthropometric phenotypes in several 
human recessive disorders. The goal of our study is to extend this observation and determine 
whether gene KOs of modest phenotypic effect also contribute to anthropometric trait variation in 
the general human population. We developed a statistical method to test for association between 
predicted gene KOs and quantitative human phenotypes and characterized the distribution of 
predicted gene KOs in 2,772 European Americans and 1,726 African Americans from the 
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National Heart, Lung, and Blood Institute (NHLBI) Exome Sequence Project (ESP). We then 
applied our method to detect associations between gene KOs and three quantitative 
anthropometric traits (body mass index (BMI), adult height, and BMI-adjusted waist-to-hip ratio 
(WHR)) using high coverage whole-exome sequence (WES) data from 4,498 ESP participants, 
low coverage whole-genome sequence (WGS) data from 1,969 French Canadians, and >100,000 
participants from the GIANT Consortium genotyped on an exome array.  
 
RESULTS 
Number and distribution of predicted gene KOs in ESP  
 We identified 18,137 and 21,935 LoF variants in 1,726 African Americans and 2,772 
European Americans from ESP, respectively (Table 1, Table S1). These LoF variants included 
protein truncating (nonsense, frameshift indel), stop-loss and splice site variants. On average, we 
found 65 and 39 rare or low-frequency LoF variants (MAF <5%) per African-American and 
European-American ESP participant, respectively (Table 1). These numbers are higher than 
some of the previous estimates (12, 16, 18), mostly because we included frameshift indels in our 
analyses. When excluding frameshift indels, we found on average 26 and 16 LoF variants with 
MAF <5% per ESP African American and European American, respectively. Descriptive 
statistics on the number of LoF variants in ESP after excluding frameshift indels are available in 
Table S2. We screened the ESP dataset for individuals who are homozygous or compound 
heterozygous for LoF variants, and are therefore predicted KOs for a given gene. To detect 
compound heterozygosity, we used phased genotype information generated with the software 
Beagle to distinguish between LoF variants inherited in cis or trans (Table 1) (19). The 
identification of LoF variants depends on the gene annotation used. To address this concern, we 
re-analyzed the ESP WES data using the GENCODE basic transcripts annotation instead of 
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RefSeq, and only considered variants that fell within all transcripts for a given gene. We obtained 
very similar association results between the two annotation software (Figure S1). We present 
below results generated with the RefSeq annotation.  
 
Common LoF variants are responsible for most predicted gene KOs (Figure 1, and 
Figure S2 for distributions without frameshift indels). For instance, in ESP African Americans, 
we found on average 25.9 and 2.5 predicted gene KOs per individual when analyzing all or 
rare/low-frequency LoF variants, respectively (Table 1). The corresponding numbers in 
European Americans are 23.2 and 1.1 for all and rare/low-frequency LoF variants (Table 1). 
While this article was under review, the Exome Aggregation Consortium (ExAC) reported an 
average of 35 homozygous protein-truncating variants per individual. This number is higher than 
the average number of homozygous LoF variants that we found in ESP (~21-23/participant, 
Table 1) (20). This difference might simply reflect increased power in ExAC to discover rare 
mutations owing to its larger sample size (N=60,706 vs N=4,498 for ESP). Because common LoF 
are more likely to be phenotypically neutral (13), we focused all subsequent analyses on LoF 
with MAF <5% within ethnic group or sub-study. In the ESP dataset, we found 2,071 and 1,433 
genes with both alleles inactivated by such LoF variants in at least one African American or one 
European American, respectively (Table 1). The higher number of predicted gene KOs in 
African Americans has been previously observed and is consistent with increased genetic 
diversity in African-ancestry populations (12). Overall, very few individuals shared the same 
gene KOs, most of them being found in only one individual (Figure 1). Homozygosity of LoF 
variants is responsible for the majority of these KO events as we only found (after taking phase 
information into account) compound heterozygous individuals for ~8% of the genes with at least 
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one gene KO (Table 1). Stop-loss variants might not be as detrimental as other categories of LoF 
variants, but they are implicated in less than 0.9% of all gene KOs identified in ESP. 
 
Predicted gene KO associated with anthropometric traits in ESP  
We tested our newly developed method (Figure 2) on three anthropometric traits (BMI, 
height, and WHR) that are available in a large number of ESP participants. We stratified our 
analyses by ethnicity and meta-analyzed association results (Figure 3). Assuming that most 
genes are independent and given the number of genes for which we could find at least one 
predicted knocked out individual, we used the following Bonferroni-corrected significance 
threshold to declare significance: α=2x10-5. No single genes reached this significance threshold 
for any of the three tested anthropometric traits after meta-analysis (Table S3).  
 
To increase statistical power, we attempted to replicate genes with a nominal P<0.05 in 
the ESP dataset using the WGS data from the MHI Biobank (N=1,976). We limited our analysis 
to genes with at least two KO individuals. Although the MHI Biobank dataset results from low-
pass WGS, the number of identified LoF variants and gene KOs was similar to the number 
observed in ESP (Table S1), suggesting that the data is sufficiently comprehensive to support 
these analyses. We found that 30-40% of gene KOs in ESP were also knocked out in the MHI 
Biobank, highlighting the challenge to replicate such studies in humans. This might particularly 
be true for gene KOs observed only in ESP African Americans given that the MHI Biobank 
includes individuals of European ancestry. We combined the ESP and MHI Biobank results but 
we did not observe any significant associations with quantitative anthropometric traits (Table S3). 
We report results with a meta-analysis P<0.005 in Table 2. The most promising gene KO 
association that we found is between PKHD1L1 and lower BMI:  we found 20 KO individuals for 
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this gene who have on average a BMI that is 0.8 standard deviation (SD) below the population 
mean (corresponding to ~-3.6 kg/m2). PKHD1L1 may play a role in immunity (21).  
 
While examining the top candidate genes, we noticed that PKHD1L1 is a large gene (78 
exons, coding sequence is ~14 kilobases), raising the possibility that our method could favor 
longer genes. In the ESP dataset, we found, as expected, that the number of LoF variants in a 
given gene is strongly correlated with the length of the coding sequence or the number of exons 
(all P<1x10-67). However, the number of individuals who carry a rare gene KO is not correlated 
with the length of the coding sequence or the number of exons of the gene (all P>0.2), except for 
a weak correlation observed in ESP African Americans with the length of the coding sequence 
(Pearson’s r=0.066, P=0.003). To exclude the possibility that gene length may influence our 
results, we tested correlations with association results from the ESP and MHI Biobank combined 
analyses. With one exception (among 12 correlation tests performed), we found no significant 
correlations between the length of the coding sequence or the number of exons and association P-
values for BMI, height, and WHR (all P>0.25). In ESP African Americans, there was a weak 
correlation between the length of the coding sequence and the BMI P-values (Pearson’s r=0.069, 
P=0.002), but it was in the opposite direction from our expectations (shorter genes have slightly 
more significant P-values). Together, these analyses suggest that our method to test association 
between gene KOs and human quantitative traits is largely insensitive to gene length. 
 
Gene KO identification and association testing using exome array data 
 Recognizing that the main limitation of our analysis is sample size, we contacted studies 
that are involved in the GIANT Consortium. Although WES or WGS data is not readily available 
for most of these studies, they all have genotyped their participants using an exome array that 
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targets 250,000 – mostly coding – variants. We reasoned that the large sample size offered by the 
GIANT Consortium could compensate for the limited number of variants present on the exome 
array. We recruited 22 studies, totaling >102,000 individuals (BMI and height available for all, 
WHR available for >62,000 individuals). Each study ran the method locally, stratifying all 
analyses by ethnicity, and we then combined results using meta-analysis methodology (22). The 
frequency of KO events was similar in ESP and the GIANT studies. However, there were more 
singletons (genes with a single KO individual) observed in European-ancestry individuals from 
the GIANT studies because of the very large sample size (Figure S3).  
 
We present the BMI, height, and WHR meta-analysis results for the GIANT studies in 
Figure 3. As reported above for the WES sequence datasets, and despite a sample size that is 
>10-times larger, we could not detect significant associations between gene KOs and quantitative 
anthropometric traits after accounting for the number of tests performed (Table 3 and Table S4). 
The most interesting finding pertains to the association between height and inactivation of 
GRHPH: autosomal recessive Mendelian mutations in this gene cause primary hyperoxaluria type 
2 [MIM 260000](23). Primary hyperoxaluria type 1 [MIM 259900], a more severe form of the 
disease caused by mutations in AGXT, is characterized by very severe growth failure (24). 
However, the connection between primary hyperoxaluria type 2 caused by recessive mutations in 
GRHPH and growth in humans has not been as clearly documented, although there is one case 
report of a child with this disease and short stature (25). 
 
Prioritizing gene KOs using a candidate-gene approach 
We next asked whether we would increase power to detect associations between gene KO 
and anthropometric traits by restricting our analyses to strong candidate genes. We focused on 
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subsets of genes that are associated with any phenotypes in OMIM, or genes that are intolerant to 
LoF mutations based on the Residual Variation Intolerance Score (RVIS) or the probability of 
being LoF Intolerant (pLI) score (20, 26). We observed several genes that deviate from the null 
when restricting our analyses to these candidate genes, especially for the OMIM genes in the 
larger GIANT datasets for BMI and WHR (Figure 4). We also reasoned that the Mouse Genome 
Informatics (MGI) database might be a good source of candidate genes for our human KO 
experiment. We retrieved the human homologues of genes from 30 MGI phenotype categories, 
and tested them against anthropometric traits (Figure S5). Again, we observed inflation of the 
KO association results when compared to the null distribution, suggesting that some of these 
genes might influence anthropometric traits when completely inactivated. The most noticeable 
result was the distribution of test statistics in the GIANT BMI analysis for genes related to taste 
and olfaction (Figure S5). Genes related to this category were significantly enriched for genes 
with a BMI P-value<0.05 in GIANT (Fisher’s exact test P=0.008). 
 
DISCUSSION 
We developed a simple statistical method to test the association between predicted gene 
KOs and human quantitative traits. We tested our method on three quantitative anthropometric 
traits (BMI, height, and WHR) in large DNA sequencing (ESP and MHI Biobank, >6,400 
individuals) and genotyping (22 participating GIANT studies, >102,000 individuals) datasets. 
Despite this large sample size, we did not identify significant genetic associations with predicted 
gene KOs, although the association between PKHD1L1 and BMI or GRHPH and height are 
interesting and should be tested for replication. Within the limitations of our study design (sample 
size, incomplete catalogue of LoF variants), our results suggest that there are no predicted gene 
KOs with modest-to-large effect size on anthropometric trait variation in the general population. 
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This conclusion is largely consistent with results from a recent study of homozygous LoF 
variants in 1,432 individuals (17).  
 
Importantly, our approach and results can guide future gene KO studies in humans. First, 
our method assumes that all LoF alleles for a given gene will shift the phenotypic mean in the 
same direction. Although it is a sensitive approach in this first large-scale gene KO experiment 
for quantitative traits, alternative methods could explore effect on phenotypic variance. Second, 
in order to maximize our sample size, we combined datasets from different technologies (WES, 
WGS, exome array). Although we accounted for this technical heterogeneity – gene KO statistics 
were similar across datasets – this approach could have introduced unanticipated biases. Ideally, 
high coverage WGS data would be available for gene KO studies. Third, haplotype phasing of 
DNA sequence data from unrelated individuals (ESP and MHI Biobank), and the lack of phase 
information for the GIANT ExomeChip studies, has limited our ability to identify compound 
heterozygous individuals. This could impact our results as nearly 20% of all gene KOs identified 
in this study were due to compound heterozygosity. We note, however, that excluding compound 
heterozygotes from the ESP analyses had very limited impact on our results (Figure S6). Fourth, 
we only considered nonsense, splice site, stop-loss and frameshift indels as LoF variants to 
identify gene KOs. Some of these variants are likely neutral: for instance, genes are more tolerant 
to non-synonymous variants at the 3’ end of a gene, and nearby variants can rescue the effect of 
LoF alleles (12). Furthermore, we excluded missense variants from our analyses, although 
functional characterization can lead to the identification of missense alleles with strong 
phenotypic effect on human complex phenotypes (27, 28).  
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The main limiting factors of gene KO studies in humans are the sample size and the depth 
of genetic information available. We have shown that even when the sample size is very large, 
most gene KOs are identified in single individuals (Figure S3). To be successful, we will need to 
develop tools to prioritize genes or increase the number of gene KOs. One possibility may be to 
consider only genes expressed in a tissue that is relevant for the phenotype of interest (e.g. genes 
expressed in growth plates for height). Another promising solution may be to consider KOs in 
biological pathways instead of single genes as the testing unit. For instance, a researcher 
interested in blood lipid genetics could pool together all individuals that carry a gene KO in any 
of the enzymes or transporters implicated in lipid metabolism. We illustrated this candidate-gene 
approach by prioritizing OMIM disease-causing genes, genes intolerant to LoF mutations, and 
genes with relevant mouse KO phenotypes. In particular for the BMI analysis, the enrichment of 
genes with mouse homologues that disrupt taste or olfaction when inactivated is of interest 
(Figure S5). Reverse genetic strategies – finding a function to a gene by first disrupting it – have 
been very successful in model organisms. Despite early challenges, the large-scale identification 
of LoF variants and characterization of gene KOs promise to also yield interesting insights into 
human biology.  
 
MATERIALS AND METHODS 
 
Ethics statement 
 This project was approved by the Ethics Committee of the Montreal Heart Institute (#11-
1333, #2013-297, #2013-1438). 
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NHLBI Exome Sequence Project (ESP) 
We conducted our initial analysis on the final whole-exome ESP dataset, which is 
described elsewhere (9). This dataset was generated from high coverage WES (median depth 
>100X)(9). All study participants in each of the component studies provided written informed 
consent for the use of their DNA in studies aimed at identifying genetic risk variants for disease 
and for broad data sharing. Institutional certification was obtained for each sample to allow 
deposition of phenotype and genotype data in dbGaP and BAM files in the short-read archive. 
We excluded individuals based on sex mismatch between clinical database and genotype-inferred 
sex (N=13), high homozygosity (N=1), high genotyping missing rate (>10%)(N=1), if they 
appear as population outliers in principal component analyses (N=30), low concordance to 
genome-wide association study data (N=4), or unresolved participant identifiers (N=4). Moreover, 
we randomly excluded one member of each pair of duplicates (N=16), and of first- and second-
degree relatives (N=108). We also removed individuals with chronic obstructive pulmonary 
disease or asthma, as these conditions could influence anthropometric traits (N=688). Finally, we 
removed participants from the CARDIA (N=201) and MESA (N=406) studies, as requested by 
investigators from these studies. We kept individuals aged between 21 and 80 years old, height 
between 125 and 240 cm, BMI <75 kg/m2, and WHR <1.5. In total, we analyzed anthropometric 
traits in 1,726 African Americans and 2,772 European Americans (Table S1).  
 
Variant quality-control and annotation 
We phased variants in the ESP dataset using Beagle 4.0 and the default parameters (19). 
We define LoF variants as variants that create or remove stop codons (nonsense and stop-loss) 
that disrupt essential splice sites (two intronic bases at exon-intron boundaries), or that change the 
reading frame (frameshift indel). We annotated single-base pair variants using in-house custom 
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scripts and build 37.1 of the human genome reference sequence. We annotated frameshift indels 
using SeattleSeq (hg19, v.9.03, http://snp.gs.washington.edu/SeattleSeqAnnotation138/). We 
included in our analyses only frameshift indel variants that fall within validated RefSeq genes 
(release 69). After filtering out variants with a call rate <95% or a Hardy-Weinberg P<1x10-6, we 
retained in our analyses 18,137 and 21,935 LoF variants in African- and European-ancestry 
individuals, respectively (Table S1). For comparison, we also annotated ESP variants using 
Ensembl’s Variant Effect Predictor (VEP) module and basic transcripts from GENCODE. We 
obtained very similar results (Figure S1). 
  
Replication cohorts with WGS or WES data available 
We used low-pass WGS data (mean coverage 5.7X) from 2,002 French-Canadian 
participants recruited by the Montreal Heart Institute (MHI) Biobank. Genotypes were imputed 
and phased using Beagle 4.0 using the default parameters (19). Individuals were removed due to 
low or high inbreeding coefficient (N=4). Variants with Hardy-Weinberg P<1x10-8 were 
excluded. In total, 1,976 MHI Biobank participants with anthropometric traits available were 
included in the replication analyses (Table S1).  
 
GIANT Consortium ExomeChip datasets 
We analyzed Illumina ExomeChip genotype data from 22 studies that are members of the 
Genetic Investigation of ANthropometric Traits (GIANT) Consortium (Table S1). In total, 
103,838, 102,775, and 62,355 individuals were included in the BMI, height and BMI-adjusted 
WHR analyses, respectively. Individuals were from European- (N=90,927; 19 studies), African- 
(N=7,576; 2 studies), and Hispanic-ancestry (N=5,335; 1 study). To increase the number of LoF 
variants available on the ExomeChip, we broaden our definition of splice-site variants to include 
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variants located two base pairs on either side of exon-intron boundaries. This is the splice-site 
definition implemented by dbNSFP (29) and used by GIANT across the Consortium’s 
ExomeChip effort. Using the most severe annotation from ENSEMBL’s VEP tool, we found that 
17.8% (797/4483) of these splice site-variants disrupt a canonical splice-site, 46.7% (2094/4483) 
are missense variants, and 31.6% (1419/4483) affect a nucleotide around the splice-site (1-3 
bases within exon or 3-8 bases within intron). Phasing information was not available for the 
GIANT exome array data. Because we focused on rare variants, we assumed that when two rare 
LoF variants were observed in the same gene in the same individual, they were inherited in trans 
to create a compound heterozygous gene KO.  
 
Statistical analyses 
We developed a flexible method to determine if the complete inactivation of genes by 
LoF variants is associated with human quantitative traits (Figure 2). For each gene, our method 
searches for individuals that are either homozygotes or compound heterozygotes for LoF 
variants; we refer to these individuals as predicted KOs. For X-linked markers that fall outside of 
the pseudoautosomal regions, we consider predicted gene KOs in men if they carry a single LoF 
variant. For compound heterozygosity, we use phase information to distinguish LoF variants that 
segregate on the same haplotype (in cis) or on different haplotypes (in trans). When phasing 
information is not available (e.g. GIANT ExomeChip data), we assume that rare LoF variants 
segregate on different haplotypes. The method then calculates for each gene the phenotypic mean 
in predicted KO individuals. Finally, it computes statistical significance using phenotype 
permutations, as follows: 
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, 
 
where  is the indicator function, m is the observed mean phenotype in predicted KO individuals, 
mi is the ith permuted mean, n is the number of permutations, Pleft and Pright are the left- and right-
tail P-values, and Pfinal is the reported two-tailed P-value. Using simulated null phenotypes and 
the ESP dataset, we showed that the test is well-calibrated (Figure S4). This method assumes that 
gene inactivation results in the same phenotypic effect (increase or decrease trait value) in all 
predicted KO individuals for a given gene. The current implementation of our method also 
currently assumes that tested individuals are unrelated and that the phenotypic distributions are 
symmetrical. It is compatible with standard genotype file formats (e.g. PLINK, vcf). The scripts 
to run our method are publicly available at: http://www.mhi-humangenetics.org/en/resources.  
 
Association of rare predicted gene KOs with anthropometric traits 
We analyzed BMI, adult height and BMI-adjusted WHR. We stratified all our analyses by 
ethnic group, and we only considered rare or low-frequency LoF variants with MAF <5%. We 
used 10,000 permutations to assess statistical significance. For genes with an empirical P<2x10-4 
(i.e. permuted means were never higher (or lower) than the observed mean among 10,000 
permutations), we re-ran the analysis using 100,000 permutations: only two genes fell in that 
category (BRPF1 Pheight=1.8x10-4; SPZ1 PWHR=2.2x10-4). For ESP samples, we corrected 
anthropometric traits for sex, age, ESP phenotype groups, exon capture reagents and the first 
three principal components, as recommended by the ESP investigators. We then applied inverse 
normal transformation on the residuals from the previous correction. For the MHI Biobank, and 
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the GIANT studies, each anthropometric trait was corrected for sex, age, age-squared and the first 
ten principal components, and we normalized the resulting residuals using inverse normal 
transformation. Taking into account the direction of the effect, we combined results across 
studies using a weighted Z-score meta-analysis method implemented in the software METAL, 
where the weight is the sample size of the corresponding study (22). To estimate statistical power 
of our approach, we modeled the effect of a recessive LoF variant on a normally distributed 
quantitative trait, as previously described (30).  This is a simplistic model as we ignore the 
presence of additional LoF variants in the same gene, which are considered in our method 
because they can lead to additional individuals that have a predicted gene KO. We assume that 
the variant has a MAF=5%, explains 1% of the genetic variance, and used a sample size of 
N=4,500 (corresponding to ESP), α=2x10-5 (Bonferroni correction for the number of genes with 
KOs), and 5,000 simulations to perform power calculations. Under this scenario, our gene KO 
approach would have 95% power to detect the association. Alternatively, testing the association 
while assuming that the variant has an additive effect would result in only 3% power. Using the 
same assumptions, we estimated 64% and 1% power for a variant that explains 0.5% of the 
variance when tested using our gene KO methodology or a simple additive model, respectively. 
 
Candidate-gene enrichment analyses 
We explored whether prioritizing gene KOs into different categories could increase the 
chance to reveal an association. First, we investigated whether the gene was an OMIM disease-
causing gene, as defined elsewhere (26). Next, we considered whether the genes were LoF 
intolerant by either having a Residual Variation Intolerance Score (RVIS) < 15% of the RVIS 
scores for all genes in the human genome (release 0.3) or a probability of being LoF intolerant 
(pLI) score > 0.9 (20, 26). We looked for enrichment by overlapping the QQ-plots of genes 
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belonging to these different categories separately on the QQ-plot containing all genes. We also 
created subsets of genes based on 30 phenotype categories from the Mouse Genome Informatics 
(MGI) Database (31). We tested the enrichment using Fisher’s exact test.  
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FIGURE LEGENDS 
Figure 1. Distributions of the number of NHLBI Exome Sequence Project (ESP) participants 
with predicted gene knockouts (KOs). We present distributions in African Americans (A and B) 
and European Americans (C and D). We include all loss-of-function (LoF: nonsense, stop-loss, 
splice site, frameshift indel) variants in A and C, whereas only rare/low-frequency LoF variants 
(minor allele frequency <5%) are included in B and D. Homo., gene KO due to homozygosity; 
Comp. het., gene KO due to compound heterozygosity; Both, genes with homozygous and 
compound heterozygous LoF variants.  
 
Figure 2. Schematic representation of the method to detect association between gene knockouts 
(KOs) and human quantitative variation. This example depicts a fictive gene with three exons 
(GENE1) that contains several SNPs. Our analytical framework only considers loss-of-function 
(LoF) variants (shown in red). GENE1 KOs are individuals who are either compound 
heterozygous of homozygous for LoF variants (individual 1 and 2). The histogram shows the 
distribution of a normalized human quantitative trait. Our method tests whether individuals that 
are KOs for a given gene (red arrows) have on average more extreme phenotypes than the rest of 
the individuals.  
 
Figure 3. Quantile-quantile (QQ) plots of association results between predicted gene knockouts 
(KOs) and anthropometric traits in the (A-C) NHLBI Exome Sequence Project (ESP) and (D-F) 
GIANT ExomeChip datasets. In these datasets, we only considered loss of function (LoF) 
variants (nonsense, stop-loss, splice site, frameshift indels (ESP only)) with a minor allele 
frequency (MAF) <5%. We analyzed three anthropometric traits: (A) body mass index (BMI) 
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(Nparticipants=4,475), (B) height (Nparticipants=4,423), and (C) waist-to-hip ratio (WHR) 
(Nparticipants=2,973). We performed these analyses stratified by ethnicity, and then combined the 
European American and African American results using meta-analysis methodology. We 
analyzed the same traits in the GIANT dataset: (D) BMI (Nparticipants=103,838), (E) height 
(Nparticipants=102,775), and (F) WHR (Nparticipants=62,355). Results are not corrected for the 
genomic inflation factor. The dash lines correspond to the 95% confidence interval. λGC, genomic 
inflation factor; Ngene, number of genes with at least one participant that carries two LoF alleles.   
 
Figure 4. Quantile-quantile (QQ) plots of association results between predicted gene knockouts 
(KOs) in candidate-genes and anthropometric traits. We restricted these analyses to OMIM 
disease-causing genes (green), genes with Residual Variation Intolerance Score (RVIS) score < 
15% of RVIS scores for all genes in the human genome (red), or genes with a probability of 
being loss-of-function intolerant (pLI) score > 0.9 (blue). We report results for three 
anthropometric traits in the NHLBI Exome Sequence Project (ESP): (A) body mass index (BMI) 
(Nparticipants=4,475), (B) height (Nparticipants=4,423), and (C) waist-to-hip ratio (WHR) 
(Nparticipants=2,973). We also report results for the same traits in the GIANT ExomeChip datasets: 
(D) BMI (Nparticipants=103,838), (E) height (Nparticipants=102,775), and (F) WHR 
(Nparticipants=62,355). Results are not corrected for the genomic inflation factor. The dash lines 
correspond to the 95% confidence interval. λGC, genomic inflation factor; Ngene, number of genes 
with at least one participant that carries two LoF alleles.   
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TABLES 
 
Table 1. Number and frequency of predicted gene knockouts (KO) in 1,727 African 
Americans and 2,772 European Americans from the NHLBI Exome Sequence Project 
(ESP). For this loss-of-function (LoF) variant analysis, we consider autosomal nonsense, stop-
loss and splice site variants, as well as frameshift insertion-deletions (indels). Rare LoF variants 
have a minor allele frequency <5%. In the absence of phasing information, we assume that rare 
LoF are inherited in trans. As expected, considering phased genotype information significantly 
impacts the number of gene KOs that we can detect due to compound heterozygosity. 
     NOT PHASED PHASED 
   Variants 
/individuals 
Variants 
/gene 
Gene KOs 
/individuals 
Number 
of KO 
genes 
Gene KOs 
/individuals 
Number 
of KO 
genes 
African 
Americans 
All LoF 
(N=18,137) 
 
237 0.92 33.7 2,530 25.9 2,429 
 Homozygotes   23.2 2,384 23.2 2,384 
 Compound 
heterozygotes   10.4 601 2.6 334 
Rare LoF 
(N=17,446) 
 
65 0.89 4.2 2,174 2.5 2,071 
 Homozygotes   2.3 2,028 2.3 2,028 
 Compound 
heterozygotes   1.9 381 0.2 155 
European 
Americans 
All LoF 
(N=21,935) 
 
197 1.12 28.8 1,844 23.2 1,741 
 Homozygotes   21.3 1,694 21.3 1,694 
 Compound 
heterozygotes   7.6 487 1.9 247 
Rare LoF  39 1.09 1.8 1,538 1.1 1,433 
28 
(N=21,351) 
 Homozygotes   1 1,390 1.01 1,390 
 Compound 
heterozygotes  
 
0.8 318 0.09 124 
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Table 2.  Association of gene knockouts (KOs) with anthropometric traits in the Exome 
Sequence Project (ESP) and Montreal Heart Institute (MHI) Biobank DNA sequencing 
datasets. We attempted to replicate gene KO associations from the ESP whole-exome DNA 
sequencing dataset in the MHI Biobank whole-genome DNA sequencing dataset. We tested for 
replication genes with P<0.05 and at least two KO individuals in the ESP dataset. We report 
genes with a combined P<0.005. We provide the mean gene KO effect size in standard deviation 
(SD) and metric units, assuming that 1 SD corresponds to 4.5 kg/m2, 6.4 cm, and 0.07 for BMI, 
height, and WHR respectively. NKO: number of individuals that are KO for the given gene. EA: 
European-ancestry; AA: African-ancestry. 
  ESP MHI Combined 
Trait Gene 
Mean EA 
(real 
units) 
NKO 
EA 
Mean AA 
(real 
units) 
NKO 
AA 
P 
Mean 
(real 
units) 
NKO P 
Weighted 
average 
(real 
units) 
P 
BMI 
PKHD1L1 
0.7 
(+3.2 
kg/m2) 
11 
0.5 
(+2.3 
kg/m2) 
6 0.009 
1.6 
(+7.2 
kg/m2) 
3 0.009 
0.8 
(+3.6 
kg/m2) 
0.0002 
PLIN4 
2.7 
(+12.2 
kg/m2) 
1 
3.1 
(+14.0 
kg/m2) 
1 
5x10-
5 
-0.2 
(-0.9 
kg/m2) 
2 0.67 
1.4 
(+6.3 
kg/m2) 
0.002 
Height 
RMDN2 NA 0 
-1.1 
(-7.0 cm) 
4 0.03 
-1.6 
(-10.2 
cm) 
2 0.02 
-1.3 
(-8.3 cm) 
0.002 
ASIC4 
3.6 
(23.0 cm) 
1 
1.5 
(9.6 cm) 
2 
5x10-
5 
-0.4 
(-2.6 cm) 
2 0.56 
1.2 
(+7.7 cm) 
0.002 
SH2B2 -1.6 2 NA 0 0.02 -1.9 1 0.06 -1.7 0.003 
30 
(-10.2 cm) (-12.2 
cm) 
(-10.9 cm) 
WHR C1QTNF5 0.6 (+0.04) 1 1.8 (+0.13) 2 0.04 
1.5 
(+0.11) 
2 0.03 1.4 (0.10) 0.003 
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Table 3. Top association results between anthropometric traits and predicted gene 
knockouts (KOs) identified using ExomeChip data from 22 studies participating in the 
GIANT Consortium. We only report genes with P<0.005 and at least two KO individuals. The 
weighted mean corresponds to the average phenotype (in standard deviation units) of individuals 
that are KO for this gene. NKO: number of individuals with a KO gene; Nstudy: number of studies 
with at least one KO individual for a given gene. 
Trait Gene NKO Nstudy Weighted 
mean (SD) 
P 
BMI CYP20A1 100 15 -0.35 0.001 
ME2 2 2 -1.90 0.002 
KIAA1024 7 5 -0.75 0.002 
TBC1D5 4 3 1.05 0.003 
LRRC39 147 16 0.23 0.003 
TAS1R1 191 6 0.15 0.004 
LAMA3 9 2 -1.02 0.004 
KIAA0391 3 2 -1.64 0.004 
TAS2R60 2 2 -2.04 0.005 
Height GRHPR 2 2 -2.28 0.0001 
ABCB7 365 10 -0.12 0.0003 
ZDHHC14 3 2 -2.01 0.0003 
ZFPM1 21 3 -0.60 0.0008 
DHX57 2 2 -2.04 0.0009 
CD8A 2 2 2.35 0.001 
CDC42BPA 4 2 1.70 0.001 
NSUN4 13 3 -0.78 0.002 
32 
ARPC5L 6 2 -1.25 0.002 
CCDC125 45 9 0.35 0.002 
BOK 27 4 0.61 0.003 
NSRP1 9 1 -1.00 0.003 
TEX13A 2 1 2.00 0.004 
RPGRIP1 10 4 -0.72 0.004 
SCGN 6 5 -0.96 0.005 
WHR C18orf56 7 1 1.39 0.0002 
AARS2 3 2 -1.78 0.001 
C18orf34 6 3 1.27 0.002 
CCDC68 13 1 0.83 0.002 
HRG 3 2 -1.52 0.004 
SPTA1 2 2 1.86 0.004 
SPTBN5 191 11 0.15 0.005 
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ABBREVIATIONS 
BMI: Body mass index 
ESP: Exome Sequence Project 
GIANT: Genetic Investigation of ANthropometric Traits 
KO: Knockout 
LoF: Loss-of-function 
MAF: Minor allele frequency 
MHI: Montreal Heart Institute 
WES: Whole-exome DNA sequencing 
WGS: Whole-genome DNA sequencing 
WHR: Waist-to-hip ratio 
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